The sensor launched in August and can be used by any adult who doesn't take insulin. The report reflects Dexcom's effort to make Stelo more personalized and engaging for consumers as it works to ...

In March, the U.S. Food and Drug Administration cleared Stelo, a CGM option developed by DexCom for people not using insulin therapy. That includes many patients with type 2 diabetes and even ...

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo ...

In August, DexCom announced the availability of Stelo, the first over-the-counter CGM biosensor in the United States for people with type II diabetes who do not use insulin. The expansion in the ...

Dexcom meanwhile currently occupies around 74% of the CGM market share in the US, according to analysis by GlobalData. The diabetes company also announced its 2025 outlook at the JP Morgan 2025 ...

if a person with diabetes used the company’s G7 sensor and app to share their glucose data with healthcare providers or family members. Dexcom had taken Abbott to court in the EU in early 2024 ...